Market Research Logo

Global Immune Checkpoint Inhibitors Market 2019-2023

Global Immune Checkpoint Inhibitors Market 2019-2023

About this market

The growing number of cancer cases being diagnosed across the globe. Various international and national level campaigns are conducted to increase the awareness about cancer and to help early detection of the disease. Technavio’s analysts have predicted that the immune checkpoint inhibitors market will register a CAGR of almost 3% by 2023.

Market Overview

High target affinity and specificity of immune checkpoint inhibitors drugs

Most of the approved therapies for cancer treatment have severe side effects, which lowers the patient compliance towards the treatment. Thus, these drawbacks help the immune checkpoint inhibitors market grow.

High costs associated with the treatment

Treatment cost is one of the major challenges for cancer patients. The high cost is mainly due to hospitalization, laboratory costs, and novel immunotherapies.

For the detailed list of factors that will drive and challenge the growth of the immune checkpoint inhibitors market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including AstraZeneca and Bristol-Myers Squibb the competitive environment is quite intense. Factors such as the high target affinity and specificity of immune checkpoint inhibitors drugs and the growing number of cancer cases being diagnosed across the globe will provide considerable growth opportunities to immune checkpoint inhibitors manufactures. AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, and F. Hoffmann-La Roche are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’


PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
PD-1 inhibitors - Market size and forecast 2018-2023
CTLA-4 inhibitors - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
Americas - Market size and forecast 2018-2023
EMEA - Market size and forecast 2018-2023
APAC - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
AstraZeneca
Bristol-Myers Squibb
F. Hoffmann-La Roche
Merck Sharp & Dohme
Pfizer
PART 14: APPENDIX
List of Abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global oncology drugs market
Exhibit 02: Segments of global oncology drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: PD-1 inhibitors - Market size and forecast 2018-2023 ($ billions)
Exhibit 20: PD-1 inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 21: CTLA-4 inhibitors - Market size and forecast 2018-2023 ($ billions)
Exhibit 22: CTLA-4 inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 23: Others - Market size and forecast 2018-2023 ($ billions)
Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas - Market size and forecast 2018-2023 ($ billions)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ billions)
Exhibit 33: Patient assistance program by AstraZeneca
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC - Market size and forecast 2018-2023 ($ billions)
Exhibit 37: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Patient assistance programs
Exhibit 42: Combined action of PD-1 and CTLA-4 checkpoint inhibitors
Exhibit 43: Treatment costs of immune checkpoint inhibitor therapeutics in US
Exhibit 44: Side effects of immune checkpoint inhibitors
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Some of the strategic alliances in global immune checkpoint inhibitors market
Exhibit 47: Approved drugs with respect to their cancer indications
Exhibit 48: Expansion of research areas of approved drugs
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: AstraZeneca - Vendor overview
Exhibit 55: AstraZeneca - Business segments
Exhibit 56: AstraZeneca - Organizational developments
Exhibit 57: AstraZeneca - Geographic focus
Exhibit 58: AstraZeneca - Segment focus
Exhibit 59: AstraZeneca - Key offerings
Exhibit 60: AstraZeneca - Key customers
Exhibit 61: Bristol-Myers Squibb - Vendor overview
Exhibit 62: Bristol-Myers Squibb - Business segments
Exhibit 63: Bristol-Myers Squibb - Organizational developments
Exhibit 64: Bristol-Myers Squibb - Geographic focus
Exhibit 65: Bristol-Myers Squibb - Key offerings
Exhibit 66: Bristol-Myers Squibb - Key customers
Exhibit 67: F. Hoffmann-La Roche - Vendor overview
Exhibit 68: F. Hoffmann-La Roche - Business segments
Exhibit 69: F. Hoffmann-La Roche - Organizational developments
Exhibit 70: F. Hoffmann-La Roche - Geographic focus
Exhibit 71: F. Hoffmann-La Roche - Segment focus
Exhibit 72: F. Hoffmann-La Roche - Key offerings
Exhibit 73: F. Hoffmann-La Roche - Key customers
Exhibit 74: Merck Sharp & Dohme - Vendor overview
Exhibit 75: Merck Sharp & Dohme - Business segments
Exhibit 76: Merck Sharp & Dohme - Organizational developments
Exhibit 77: Merck Sharp & Dohme - Geographic focus
Exhibit 78: Merck Sharp & Dohme - Segment focus
Exhibit 79: Merck Sharp & Dohme - Key offerings
Exhibit 80: Merck Sharp & Dohme - Key customers
Exhibit 81: Pfizer - Vendor overview
Exhibit 82: Pfizer - Business segments
Exhibit 83: Pfizer - Organizational developments
Exhibit 84: Pfizer - Geographic focus
Exhibit 85: Pfizer - Segment focus
Exhibit 86: Pfizer - Key offerings
Exhibit 87: Pfizer - Key customers

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report